Truffle Capital

Truffle Capital is a Paris-based venture firm with a long track record in deeptech, medical devices, and biotechnology. The firm operates an in-house incubator that builds companies around proprietary intellectual property, often emerging from research collaborations and corporate spinouts, in addition to backing externally founded startups. For physician AI founders working at the boundary of devices, robotics, biology, and software, Truffle is one of the more credible French names with the appetite to invest behind hard science.

The thesis covers medical devices, interventional robotics, minimally invasive technologies, and biotech, with computational and AI elements appearing where the underlying science demands them. Within medical devices, the team has incubated and backed companies including HoliStick Medical, illustrating their willingness to commit early to capital-intensive, regulatory-heavy technologies. Pure software-only digital health, consumer wellness, and AI applications without a hardware or clinical depth are less natural fits.

Check sizes typically range from one to five million dollars at seed and Series A, with follow-on capacity in subsequent rounds. The firm is comfortable leading rounds in companies it has incubated and co-investing in external opportunities. Geography is France and broader Europe, with strong French focus.

The partner team has deep scientific and operating backgrounds and is supported by an in-house technical and incubation team that helps spin out companies from concept to first round. Diligence is rigorous on technology, IP, regulatory pathway, and reimbursement, and the firm is comfortable with longer timelines to commercial milestones than a generalist Series A fund.

The right way to approach is through a French scientific or clinical advisor, a corporate finance contact in Paris, or a portfolio CEO. The incubation programme is the entry point for IP-rich projects looking for venture-builder-style support; external founders pitch as a more traditional venture process. When you reach out, lead with the science, the IP position, the regulatory and reimbursement path, and the clinical evidence plan. Bring a credible team that combines clinical, scientific, and operational depth. The right time to engage is when the underlying technology has matured to the point where a credible regulatory and commercial plan is possible, and where seed or Series A capital can fund the next defined milestone. Pure software founders without a hardware or biology core, or founders without a credible regulatory plan, will find better fits at digital health-specialist funds; founders building serious medtech or biotech companies in France will find Truffle a serious option.